Not Signed In - [ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Crohn's Disease |
Crohn's disease; Crohn//'s disease; Inflamatory Bowel Disease; Inflammatory Bowel Disease, Crohn's |
Clinical Trial: Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
This study is no longer recruiting patients.
|
Purpose
The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderate to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Crohn's Disease | Drug: natalizumab | Phase III |
MedlinePlus related topics: Crohn's Disease
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase 3, international, multicenter, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of intravenous Antegren (natalizumab) in maintaining clinical response and remission in subjects with Crohn's disease
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
More Information
Record last reviewed: January 2003
Last Updated: October 13, 2004
Record first received: April 3, 2002
ClinicalTrials.gov Identifier: NCT00032786
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
